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Dr Acar: It is clear from what we have heard that it is 
very difficult to have any precise etiologic diagnosis in 
community-acquired pneumonia. We have two main 
groups of agents, the macrolides and the p-lactams. We 
know that there is some advantage with the macrolides 
in terms of the number of species susceptible, which is 
a little greater than for some of the p-lactams. If the 
physician treating the patient has no clinical reason to 
choose between the p-lactam or macrolide as first line, 
is it appropriate to use one for, say, three days then and 
re-evaluate the patient and if there is no improvement 
change the treatment to the other group of com- 
pounds? Would this improve our way of using two 
groups of compounds which both obviously have good 
reason to be used in respiratory tract infections? 
Dr Ronald: For bacterial pneumonias due to Pneu- 
mococci, where studies have been done, patients begin 
to improve between 24 and 72 h and they are 
substantially better by 72 h. With Mycoplasma the 
improvement is less acute and patients may still feel just 
as unwell 2 to 3 days into their illness. But I do not 
think that the patient needs to return for a visit. I am 
happy giving the patient instructions that if they are not 
substantially better between 48 and 72 h then I want to 
see them again, and I give them criteria for saying that 
they are substantially better. If, on re-evaluation, I have 
concerns that either I have missed something or that 
the patient really is not responding, I would switch 
from amoxycillin to a macrolide at  72 h. 
Dr Rubinstein: I agree that 72 h is a good time to 
have the first reassessment. I would like to add one 
more comment. We have heard at this Nineteenth ICC 
Meeting quite alarming news about the spread of 
penicillin resistance among Streptococcus viridans as well 
as Stveptococcus pneurnoniae. Some places report 30-60%. 
This really changes the picture. I ask myself if it is not 
time really to start looking at what we are doing with 
these antibiotics. Now is the time that we are starting 
to pay back for our negligence in the past. This is a 
particular problem for a patient, say, with mitral valve 
prolapse, who might be susceptible in the future. You 
may be left with a drug of no choice, which is 
vancomycin. If we really look into the future I think 
that we might be very sparing with the use of regular 
penicillins. 
Dr Ronald: I do not think that we know how to use 
antimicrobial agents so as not to develop resistance and 
that is one of the big unanswered questions. For my 
standard patient, I would probably only prescribe 
antibacterial therapy for 5 days. I do not think there is 
any evidence that we need to prescribe it for 7 or 10 
or 14 days for 95% of those patients who present with 
pneumonia. Nor do I think we understand how to 
prevent development of resistance when we use 
macrolides or penicillins. 
Dr Rubinstein: What we can do is choose between 
antibiotics. This is the only decision available. And you 
may have to decide for yourselfwhat drug in the future 
you are prepared to sacrifice. Because whatever you use 
you will develop resistance. Five years from now you 
may have to abandon a particular drug because 
everything is resistant to it. 
Dr Acar: I am glad you agree that evaluation on the 
third day is a good way of deciding on any need to 
change the class of antibiotic you are using. I am more 
than happy to encourage the microbiologists to study 
the resistance problem. However, I do not advocate not 
using any more penicillin because we do not really 
know where the resistance is created, and if it is stable. 
For those strains of S. pneurnoniae that are higher in 
terms of MIC, I will treat them with an adequately high 
dosage. Low dosage has been the problem, particularly 
with some oral cephalosporins. Many of them have 
been prescribed at a dosage which was exactly at the 
limit. High dosage and shorter duration of treatment is 
the best way to protect against resistance. 
And now it only remains for me to thank you all 
for attending, and to thank Hoechst Roussel for 
organizing this Seminar. 
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